Home » Stocks » Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc. (CPRX)

Stock Price: $3.34 USD -0.93 (-21.71%)
Updated Aug 11, 2020 3:59 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 344.93M
Revenue (ttm) 118.99M
Net Income (ttm) 42.95M
Shares Out 103.43M
EPS (ttm) 0.41
PE Ratio 8.13
Forward PE 12.02
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $3.34
Previous Close $4.26
Change ($) -0.93
Change (%) -21.71%
Day's Open 3.91
Day's Range 3.26 - 3.96
Day's Volume 9,248,912
52-Week Range 2.55 - 7.67

More Stats

Market Cap 344.93M
Enterprise Value 243.74M
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 103.43M
Float 90.74M
EPS (basic) 0.42
EPS (diluted) 0.41
FCF / Share 0.48
Dividend n/a
Dividend Yield n/a
Earnings Yield 12.29%
FCF Yield 14.43%
Payout Ratio n/a
Shares Short 12.09M
Short Ratio 7.13
Short % of Float 12.10%
Beta 1.85
PE Ratio 8.13
Forward PE 12.02
P/FCF Ratio 6.93
PS Ratio 2.90
PB Ratio 4.30
Revenue 118.99M
Operating Income 43.51M
Net Income 42.95M
Free Cash Flow 49.77M
Net Cash 101.19M
Net Cash / Share 0.98
Gross Margin 73.57%
Operating Margin 36.57%
Profit Margin 36.10%
FCF Margin 41.83%
ROA 30.39%
ROE 56.94%
ROIC 242.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 6
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(147.38% upside)
Current: $3.34
Target: 8.25
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth20361.27%---------
Gross Profit87.550.50--------
Operating Income31.82-35.30-18.68-19.28-20.40-14.59-10.31-5.22-6.08-4.51
Net Income31.88-34.00-18.41-18.07-20.23-15.51-12.15-4.08-6.39-4.01
Shares Outstanding10310385.8082.8880.8664.1445.4530.0321.7318.58
Earnings Per Share0.30-0.33-0.21-0.22-0.25-0.24-0.27-0.14-0.29-0.22
Operating Cash Flow34.61-26.15-13.74-17.96-18.02-12.94-9.88-5.14-4.99-3.76
Capital Expenditures-0.02-0.09--0.10-0.02-0.06-0.01-0.05--
Free Cash Flow34.59-26.24-13.74-18.06-18.04-13.00-9.89-5.19-4.99-3.76
Cash & Equivalents94.5353.4984.0240.4158.4139.2823.7215.436.045.49
Total Debt0.65---------
Net Cash / Debt93.8853.4984.0240.4158.4139.2823.7215.436.045.49
Book Value87.6350.7880.9639.3155.4835.2421.3914.623.765.52
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Catalyst Pharmaceuticals, Inc.
Country United States
Employees 76
CEO Patrick J. McEnany

Stock Information

Ticker Symbol CPRX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CPRX
IPO Date November 8, 2006


Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. Catalyst Pharmaceuticals, Inc. has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.